Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT00530023 (STAR2) für Typ-1-Diabetes ist abgeschlossen. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness (STAR2) Phase 4 29 Multizentrisch
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT00530023 (STAR2) untersuchte Behandlung im Zusammenhang mit Typ-1-Diabetes. Diese interventionsstudie der Phase 4 hat den Status abgeschlossen. Die Studie begann am 1. Februar 2006 mit 29 Teilnehmern. Sie wurde durchgeführt von Medtronic Diabetes und am 1. September 2006 abgeschlossen. Die Daten von ClinicalTrials.gov wurden zuletzt am 10. Juni 2011 aktualisiert.
Kurzbeschreibung
Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections. Evaluate the educational materials and time required for training subjects naïve to continuous subcutaneous insulin infusion (CSII) to use the Paradigm 722 REAL Time System in preparation for a large multi-center clinical trial
Ausführliche Beschreibung
Many subjects with Type 1 diabetes continue to manage their disease utilizing multiple daily injections, but despite frequent blood glucose checks, are unable to control their glycemic variability or lower their A1C levels. The MiniMed Paradigm REAL-Time System transmits sensor glucose values to the insulin pump every 5 minutes, allowing users to view their current glucose values as well as glycemic excursions and tr...Mehr anzeigen
Offizieller Titel
Pilot Study To Identify Effective Methods Of Training Pump Naïve Subjects To Use The Paradigm® 722 System And To Describe Clinical Effectiveness Compared To Subjects Continuing With Multiple Dose Injections (MDI) of Insulin
Erkrankungen
Typ-1-DiabetesWeitere Studien-IDs
- STAR2
- CEP195/Z25
NCT-Nummer
Studienbeginn (tatsächlich)
2006-02
Zuletzt aktualisiert
2011-06-10
Studienende (vorauss.)
2006-09
Geplante Rekrutierung
29
Studientyp
Interventionsstudie
PHASE
Phase 4
Status
Abgeschlossen
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Aktives Vergleichspräparat1. 722 722 arm: MiniMed Paradigm REAL-Time System | MiniMed Paradigm REAL-Time System MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink |
Keine Intervention2. Multiple Daily Injections (MDI) MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study. | Nicht zutreffend |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change in A1C From Baseline to Week 15 | Change in A1C measured from Baseline to week 15 will be compared. A1C measured as percent of glycated hemoglobin using a standardized assay for all subjects. | Baseline and 15 weeks |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Incidence of Severe Hypoglycemia Events Baseline to Week 15 | The total number of severe hypoglycemia events, defined as episodes requiring assistance from another person (i.e., subject is unable to treat self and requires carbohydrate or glucagon or other resuscitative actions) compared between the two study arms from Baseline to Week 15. | Baseline and 15 weeks |
Blood Glucose Monitoring System - Ratings Questionnaire (BGMS-RQ) Assessed at Baseline and Week 15 | Questionnaire measuring overall satisfaction with the relevant blood glucose monitoring system. Assessed at Baseline and Week 15 and compared between arms. Likert scale used with responses graded as the lowest number being the least acceptable and the highest number the most acceptable. The scoring was then transformed to a 0 - 100 scale again with the higher number representing the most acceptable response. | Baseline and 15 weeks |
Insulin Delivery System - Ratings Questionnaire (IDS-RQ) Assessed at Baseline and Week 15 | Questionnaire measuring overall satisfaction with the relevant insulin delivery system. Assessed at Baseline and Week 15 and compared between arms. Likert scale used with responses graded as the lowest number being the least acceptable and the highest number the most acceptable. The scoring was then transformed to a 0 - 100 scale again with the higher number representing the most acceptable response. | Baseline and 15 weeks |
Hypoglycemia Fear Scale (HFS) Assessed at Baseline and Week 15 | Questionnaire evaluating change in the subjects' fear of potential hypoglycemia events assessed Week 15 and compared between arms. Likert scale of 0 - 4 used with responses graded as the lowest number being the most acceptable and highest number the least acceptable. The questionnaire has two sections, Behavior and Worry with a maximum possible score of 60 for Behavior (15 X 4) and 72 for Worry (18 X 4). The total combined scoring of these two sections was then assessed at Baseline and Week 15 and the change from Baseline to Week 15 for each arm reported as the end of study result. | Baseline and 15 weeks |
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
- Subject is between 18 - 70 years of age (inclusive)
- Subject is diagnosed with Type 1 Diabetes Mellitus as determined by the Investigator.
- Diabetes is diagnosed > (greater or equal to) six (6) months prior to study entry.
- A1C > 7.5% (greater than or equal to) as measured by the Central Laboratory at Screening Visit 1.
- Subject currently requires insulin administration by injection > (greater or equal to) three (3) times daily.
- Subject is currently (over past 3 months) performing an average of four (4) blood glucose measurements per day, as determined and documented by the investigator
- Subject has been treated in the investigator's practice or in a referring endocrinologist's practice for at least 6 months prior to the study
- Subject is fluent in speaking, understanding, and reading English.
- Subject is able and willing to perform the study procedures and agrees to wear sensors at least five (5) days per week (722 Arm only) during the study period.
- Subject is able to use the study devices (722 Arm only) as labeled
- Subject has reviewed and signed the Informed consent, HIPPA Authorization, and California Experimental Subject's Bill of Rights (California only).
- Subject has the capability to upload their insulin pumps or glucose meters every two weeks; access to the Internet and specific computer system requirements are necessary to participate in the study
- Subject is pregnant or planning to become pregnant during the course of the study.
- Subject has a history of tape allergies that have not been resolved.
- Subject self-reports any skin abnormality (i.e. psoriasis, rash, and staphylococcus infection).
- Subject has any additional condition(s) (medical, social, or psychosocial) that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing or complying with the study requirements.
- Subject is currently or within past 4 weeks participated in an investigational study (drug or device).
Subject has a history of tape allergies that have not been resolved.
Medtronic DiabetesKeine Kontaktdaten vorhanden
2 Studienstandorte in 1 Ländern
California
Diabetes Treatment Center, Loma Linda University, Loma Linda, California, 92354, United States
Oregon
Portland Diabetes & Endocrinology, Portland, Oregon, 97210, United States